These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 3089655

  • 1. Abnormal B-cell function in hemophiliacs treated with cryoprecipitate and factor VIII and IX concentrates.
    Gorski A, Gjerset GF, Martin PJ, Counts RB, Hansen JA.
    Clin Immunol Immunopathol; 1986 Sep; 40(3):447-55. PubMed ID: 3089655
    [Abstract] [Full Text] [Related]

  • 2. T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates.
    Lechner K, Niessner H, Bettelheim P, Deutsch E, Fasching I, Fuhrmann M, Hinterberger W, Korninger C, Neumann E, Liszka K.
    Thromb Haemost; 1983 Aug 30; 50(2):552-6. PubMed ID: 6314582
    [Abstract] [Full Text] [Related]

  • 3. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM, Berntorp E.
    Prog Clin Biol Res; 1990 Aug 30; 324():69-78. PubMed ID: 2106694
    [No Abstract] [Full Text] [Related]

  • 4. Immunologic studies in asymptomatic hemophiliac patients.
    Frydecka I, Kowalewska B, Lesiecki A, Kuliczkowski K, Palakowska A, Polkowski A.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986 Aug 30; 113(5):708-15. PubMed ID: 2435638
    [Abstract] [Full Text] [Related]

  • 5. HTLV III antibodies and immunological alterations in hemophilia patients.
    Seifried E, Pindur G, Stötter H, Porzsolt F, Rasche H, Erfle V, Hehlmann R, Heimpel H.
    Klin Wochenschr; 1986 Feb 03; 64(3):115-24. PubMed ID: 3005759
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Hemophilia and HTLV-III infection].
    Lechler E.
    Z Hautkr; 1986 Dec 01; 61(23):1687-704. PubMed ID: 2949442
    [Abstract] [Full Text] [Related]

  • 8. HTLV-III infection in homosexuals and hemophiliacs in Sweden.
    Biberfeld G, Böttiger B, Karlsson A, Sandström E, Morfeldt-Månsson L, Blombäck M, Nilsson IM, Wiechel B, Saxinger C, Gallo R.
    Cancer Res; 1985 Sep 01; 45(9 Suppl):4609s-4611s. PubMed ID: 2990693
    [Abstract] [Full Text] [Related]

  • 9. Lymphadenopathy-associated virus antibodies and T cells in hemophiliacs treated with cryoprecipitate or concentrate.
    Gjerset GF, McGrady G, Counts RB, Martin PJ, Jason J, Kennedy S, Evatt B, Hansen JA.
    Blood; 1985 Sep 01; 66(3):718-20. PubMed ID: 2992642
    [Abstract] [Full Text] [Related]

  • 10. Immunoglobulin G antibodies to lymphadenopathy-associated virus in differently treated French and Belgian hemophiliacs.
    Rouzioux C, Brun-Vezinet F, Couroucé AM, Gazengel C, Vergoz D, Desmyter J, Vermylen J, Vermylen C, Klatzmann D, Geroldi D.
    Ann Intern Med; 1985 Apr 01; 102(4):476-9. PubMed ID: 2983593
    [Abstract] [Full Text] [Related]

  • 11. A study of cell mediated and humoral immunity in haemophilia and related disorders.
    Moffat EH, Bloom AL, Jones J, Matthews N, Newcombe RG.
    Br J Haematol; 1985 Sep 01; 61(1):157-67. PubMed ID: 3931666
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy.
    Cuthbert RJ, Ludlam CA, Steel CM, Beatson D, Peutherer JF.
    Br J Haematol; 1992 Mar 01; 80(3):364-9. PubMed ID: 1581216
    [Abstract] [Full Text] [Related]

  • 14. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U.
    Thromb Haemost; 1999 Aug 01; 82(2):531-9. PubMed ID: 10605747
    [No Abstract] [Full Text] [Related]

  • 15. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P.
    Thromb Haemost; 1997 Jun 01; 77(6):1113-9. PubMed ID: 9241742
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Modulation of allogeneic cytotoxic activity by factor VIII or IX concentrates.
    Soria AG, Bouzas MB, Anselmo A, Ruibal-Ares BH.
    Haematologica; 1991 Jun 01; 76(1):33-7. PubMed ID: 1829058
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.